home / stock / nwphf / nwphf short
Short Information | Newron Pharms Spa Ord (OTCMKTS:NWPHF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 32,464 |
Total Actual Volume | 35,892 |
Short Trends | |
---|---|
Cover Days | 0 |
Short Days | 18 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 1,623 |
Average Short Percentage | 89.88% |
Is there a NWPHF Short Squeeze or Breakout about to happen?
See the NWPHF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
06-08-2021 | $2.8 | $2.8 | $2.8 | $2.8 | 2,000 | 2,000 | 100% |
06-01-2021 | $2.79 | $2.79 | $2.79 | $2.79 | 2,000 | 2,000 | 100% |
05-28-2021 | $2.78 | $2.8 | $2.8 | $2.78 | 6,000 | 4,000 | 66.67% |
04-12-2021 | $2.8 | $2.8 | $2.8 | $2.8 | 1,000 | 1,000 | 100% |
03-15-2021 | $3 | $3 | $3 | $3 | 8,533 | 8,533 | 100% |
10-29-2020 | $1.9 | $1.9 | $1.9 | $1.9 | 900 | 900 | 100% |
10-21-2020 | $2.55 | $2.55 | $2.55 | $2.55 | 200 | 200 | 100% |
10-15-2020 | $2.55 | $2.55 | $2.55 | $2.55 | 1,076 | 900 | 83.64% |
05-29-2020 | $8.9 | $8.9 | $8.9 | $8.9 | 2,377 | 1,125 | 47.33% |
01-09-2020 | $N/A | $7.50 | $N/A | $N/A | 40 | 40 | 100% |
12-10-2019 | $N/A | $7.50 | $N/A | $N/A | 15 | 15 | 100% |
11-06-2019 | $6.55 | $6.55 | $6.55 | $6.55 | 1,000 | 1,000 | 100% |
04-22-2019 | $N/A | $9.25 | $N/A | $N/A | 25 | 25 | 100% |
04-04-2019 | $9.25 | $9.25 | $9.25 | $9.25 | 100 | 100 | 100% |
03-29-2019 | $9.00 | $9.00 | $9.00 | $9.00 | 200 | 200 | 100% |
09-19-2018 | $11.00 | $11.00 | $11.00 | $11.00 | 100 | 100 | 100% |
08-29-2018 | $10.9508 | $10.9508 | $10.9508 | $10.9508 | 10,000 | 10,000 | 100% |
04-30-2018 | $N/A | $9.2444 | $N/A | $N/A | 76 | 76 | 100% |
01-08-2018 | $12.85 | $12.85 | $12.85 | $12.85 | 250 | 250 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Newron Pharms Spa Ord Company Name:
NWPHF Stock Symbol:
OTCMKTS Market:
Data from study 014/015, a phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) for up to one year Presentation of study design for potentially pivotal phase III trial for TRS patients Information on potentially pivotal st...
Ad hoc announcement pursuant to Art. 53 LR EIB agrees to extend repayment dates of tranches one to three of its loan to the Company until end of 2025 and into 2026, after potentially significant pipeline milestones Amended agreement envisages EIB will now receive certain performan...
Ad hoc announcement pursuant to Art. 53 LR Treatment with evenamide demonstrated significant, clinically important, progressive, sustained and long-lasting improvement on PANSS total, CGI-S and Level of Functioning (LOF) More than 70% of patients experienced clinically important reducti...